Discussion on the only adjuvant study that was positive for RCC by Chandler Park

Chandler Park posted on X:

“Dr. Scott Tykodi gives a masterful discussion on the only adjuvant study that was positive for RCC. He also gives an intriguing discussion of the use of NIVO/IPI for 1st line metastatic RCC with favorable risk.”

Source: Chandler Park/X

Chandler Park, MD, FACP is an haematologist oncologist, medical journalist, and clinical researcher. He is the Advisory Dean and Clinical Professor at University of Louisville School of Medicine. He is the Kentucky Physician Representative of the ASCO State Executive Council. He is also the Medical Oncology Board Examiner at  American Board of Internal Medicine.

Scott Tykodi, MD, PhD, is an Associate Professor in the Clinical Research Division at Fred Hutch Cancer Center and an Affiliate Investigator in the Translational Science and Therapeutics Division at Fred Hutch. He also serves as an Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine.

Dr. Tykodi focuses on applying immunotherapy advancements to treat kidney cancer, specifically developing a cellular immunotherapy targeting 5T4, a marker present on nearly all kidney cancer cells but rarely on healthy adult cells.